Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; Inhibition of p38 enhances IL-12 whilst suppressing IL-10

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 575-586

  Franks, Hester A ^a   Wang, Qunwei ^a   Lax, Stephanie J ^a   Collins, Mary K ^b   Escors, David ^c   Patel, Poulam M ^a   Jackson, Andrew M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

dendritic cell; IL 12; p38; signaling; Th1

Indexed keywords

CD1C ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE; PROTEIN MK2; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CELL COUNT; CELL FUNCTION; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84888007814     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28398     Document Type: Article

References (49)

1. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
2. Franks HA, Wang Q, Patel PM,. New anticancer immunotherapies. Anticancer Res 2012; 32: 2439-53.
3. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother, 2010; 59: 1573-82.
4. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512-20.
5. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002; 100: 1362-72.
6. Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 2003; 102: 1753-63.
7. Cravens PD, Hayashida K, Davis LS, et al. Human peripheral blood dendritic cells and monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses. Scand J Immunol 2007; 65: 514-24.
8. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76.
9. Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005; 105: 2465-72.
10. Wang Q, Franks HA, Lax SJ, et al. The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells. J Immunol 2013; 190: 3246-55.
11. Re F, Strominger JL,. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-9.
12. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen- activated protein kinase and c-Fos. J Immunol 2003; 171: 4984-9.
13. Nakahara T, Uchi H, Urabe K, et al. Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int Immunol 2004; 16: 1701-9.
14. Arrighi JF, Rebsamen M, Rousset F, et al. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001; 166: 3837-45.
15. Sato K, Nagayama H, Tadokoro K, et al. Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 1999; 162: 3865-72.
16. Aiba S, Manome H, Nakagawa S, et al. p38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Investig Dermatol 2003; 120: 390-9.
17. Re F, Strominger JL,. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology 2004; 209: 191-8.
18. Jackson AM, Mulcahy LA, Zhu XW, et al. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 2008; 123: 623-32.
19. Goetz MP, Tolcher AW, Haluska P, et al. A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer. J Clin Oncol 2012; 30:suppl.
20. Hammaker D, Firestein GS,. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 (Suppl 1): i77-i82.
21. Chung KF,. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011; 139: 1470-9.
22. Anand P, Shenoy R, Palmer JE, et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain, 2011;15:1040-8.
23. Escors D, Lopes L, Lin R, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008; 111: 3050-61.
24. Arce F, Breckpot K, Stephenson H, et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011; 63: 84-95.
25. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
26. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008; 31: 62-9.
27. Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008; 324: 921-9.
28. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006; 149: 393-404.
29. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
30. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012; 367: 1694-703.
31. Boullart AC, Aarntzen EH, Verdijk P, et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008; 57: 1589-97.
32. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
33. Smith AM, Qualls JE, O'Brien K, et al. A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J Biol Chem 2011; 286: 23582-90.
34. Wang Q, Franks HA, Porte J, et al. Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation. Immunology, 2011;134:60-72.
35. Jackson AM, Mulcahy LA, Porte J, et al. Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of T H-responses. Eur Cytokine Netw 2010; 21: 319-28.
36. Zaru R, Ronkina N, Gaestel M, et al. The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat Immunol 2007; 8: 1227-35.
37. Martin M, Rehani K, Jope RS, et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-84.
38. Vuckovic S, Gardiner D, Field K, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. J Immunol Methods 2004; 284: 73-87.
39. Della Bella S, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003; 89: 1463-72.
40. Della Bella S, Nicola S, Brambilla L, et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol (Orlando, Fla) 2006; 119: 317-29.
41. Sciarra A, Lichtner M, Autran GA, et al. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007; 67: 1-7.
42. Wilkinson R, Kassianos AJ, Swindle P, et al. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006; 66: 180-92.
43. Kim C, Sano Y, Todorova K, et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 2008; 9: 1019-27.
44. Otsuka M, Kang YJ, Ren J, et al. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 2010; 138: 1255-65, 65 e1-e9.
45. Zarubin T, Han J,. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15: 11-18.
46. Aguilera R, Saffie C, Tittarelli A, et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 2011; 17: 2474-83.
47. Lin CC, Wang TE, Liu CY, et al. Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation. Clin Invest Med 2008; 31: E150-E159.
48. Win SJ, McMillan DG, Errington-Mais F, et al. Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br J Cancer 2012; 106: 92-8.
49. Prue RL, Rossetti T, Vari F, et al. A phase 1 clinical trial of a BDCA-1+ (CD1c+) blood dendritic cell preparation loaded with control and tumour-associated antigens, for the immune therapy of metastatic refractory prostate cancer. In: 5th International Meeting on "Dendritic Cell Vaccination and other Strategies to tip the Balance of the Immune System", 2007. Bamberg, Germany.